

Influenza A(H1N1)pdm09 egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2021-2022 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

26 February 2021

Candidate vaccine viruses (CVVs) (antigenically like A/Victoria/2570/2019 (Egg derived) - Accession number (GISAID): EPI_ISL_417210

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Indiana/02/2020	Wild type virus			WHO CCs and WHO ERLs
	X-349	Classical	NYMC	NYMC, USA NIID, Japan NIBSC, UK
	X-349A	Classical	NYMC	NYMC, USA NIID, Japan NIBSC, UK
A/Victoria/2570/2019	Wild type virus			WHO CCs and WHO ERLs
	IVR-215	classical	Seqirus	
A/Victoria/3/2020	Wild type virus			WHO CCs and WHO ERLs
	IVR-216	classical	Seqirus	
A/Victoria/1/2020	Wild type virus			WHO CCs and WHO ERLs
	IVR-217	classical	Seqirus	

引用元：WHOウェブサイト

https://www.who.int/influenza/vaccines/virus/candidates_reagents/summary_a_h1n1_cvv-egg_nh21-22.pdf?ua=1

Influenza A(H3N2) egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2021-2022 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country²](#).

26 February 2021

Candidate vaccine viruses (antigenically like A/Cambodia/e0826360/2020 (egg derived) - Accession number (GISAID): EPI_ISL_806547

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Cambodia/e0826360/2020	Wild type virus			WHO CCs NIBSC, UK
	IVR-224	Classical	Seqirus	
A/Tasmania/503/2020	Wild type virus			WHO CCs NIBSC, UK
	IVR-221	Classical	Seqirus	

引用元：WHOウェブサイト

https://www.who.int/influenza/vaccines/virus/candidates_reagents/summary_a_h3n2_cvv-egg_nh21-22.pdf?ua=1



Influenza B Victoria lineage egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2021-2022 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

26 February 2021

Candidate vaccine viruses (antigenically like B/Washington/02/2019 (egg derived) - Accession number (GISAID): EPI_ISL_352076

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Hong Kong/574/2019	Wild type virus			WHO CCs
	BX-87C	Classical	NYMC	NIBSC, UK NYMC, USA
B/Washington/02/2019	Wild type virus			WHO CCs NIBSC, UK
	BX-85C	Classical	NYMC	NIBSC, UK NIID, Japan NYMC, USA
B/Brisbane/35/2018	Wild type virus			NIBSC, UK
B/Victoria/705/2018	Wild type virus			NIBSC, UK NIID, Japan
	BVR-11	Classical	VIDRL	CCDC, China FCI, UK NIBSC, UK NIID, Japan VIDRL, Australia
B/Sichuan-Gaoxin/531/2018	Wild type virus			WHO CCs
	BX-83A	Classical	NYMC	CCDC, China NYMC, USA
	CNIC-1906	Classical	CCDC	CCDC, China FCI, UK NIBSC, UK VIDRL, Australia

引用元：WHOウェブサイト

https://www.who.int/influenza/vaccines/virus/candidates_reagents/summary_b_vic_cv-egg_nh21-22.pdf?ua=1

Influenza B Yamagata lineage egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2021-2022 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

26 February 2021

Candidate vaccine viruses (antigenically like B/Phuket/3073/2013 (egg derived) - Accession number (GISAID): EPI_ISL_168822

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Phuket/3073/2013	Wild type virus			WHO CCs NIBSC, UK
	BVR-1B	Classical	Seqirus	VIDRL, Australia
B/California/12/2015	Wild type virus			CDC, USA
	BX-59A	Classical	NYMC	NIBSC, UK NYMC, USA
	BX-59B	Classical	NYMC	NIBSC, UK NYMC, USA
B/Brisbane/9/2014	Wild type virus			WHO CCs NIBSC, UK
B/Utah/09/2014	Wild type virus			CDC, USA NIBSC, UK
B/Arizona/10/2015	Wild type virus			NIBSC, UK
	BX-63	Classical	NYMC	NIBSC, UK NYMC, USA
	BX-63A	Classical	NYMC	NIBSC, UK NYMC, USA
B/Hong Kong/3417/2014	Wild type virus			NYMC, USA
	BX-57	Classical	NYMC	NIBSC, UK NYMC, USA

引用元：WHOウェブサイト

https://www.who.int/influenza/vaccines/virus/candidates_reagents/summary_b_yam_cvv-egg_nh21-22.pdf?ua=1